Acknowledgements
The authors thank the patients and their families, as well as the clinical study teams, for making this study possible; Faith E. Nathan, MD, who served as the clinical trial physician; and Suresh Alaparthy, who served as the global trial manager. This study was funded by Bristol Myers Squibb. The PD-L1 IHC 28-8 pharmDx assay was developed in collaboration with Dako, an Agilent Technologies company (Santa Clara, CA, USA). Medical writing support was provided by Vidya Rajagopalan, PhD, of Evidence Scientific Solutions, Inc., and was funded by Bristol Myers Squibb.